Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (139) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 21:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.1
- Combined market value
- ZAR 87.39T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | ZAR 1.17T | ZAR 367.43 | 1.71% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | ZAR 5.87T | ZAR 2,380.08 | 3.90% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | ZAR 103.2B | ZAR 5,160.07 | 1.67% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.7 | ZAR 172.6B | ZAR 1,142.19 | 5.44% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.2 | ZAR 851.2B | ZAR 729.50 | 0.92% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.3 | ZAR 274.7B | ZAR 4,280.10 | 2.93% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | ZAR 129B | ZAR 1,641.94 | 0.06% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.7 | ZAR 131.7B | ZAR 377.97 | 3.60% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.7 | ZAR 796.4B | ZAR 6,971.99 | 2.34% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | ZAR 128.2B | ZAR 1,171.04 | 3.25% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.1 | ZAR 8.73T | ZAR 4,940.68 | 2.33% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 44.9 | ZAR 682.1B | ZAR 1,186.24 | 0.01% down | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 44.9 | ZAR 21.28T | ZAR 23,886.31 | 2.32% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.6 | ZAR 542.9B | ZAR 880.48 | 1.91% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | ZAR 215.7B | ZAR 258.77 | 1.28% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.4 | ZAR 11.34T | ZAR 4,710.76 | 2.15% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.1 | ZAR 2.76T | ZAR 484.72 | 1.44% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.0 | ZAR 3.13T | ZAR 1,804.84 | 0.22% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.5 | ZAR 2.35T | ZAR 9,266.91 | 0.42% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | ZAR 5.06T | ZAR 2,681.18 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | ZAR 143.4B | ZAR 2,196.63 | 2.00% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | ZAR 4.79T | ZAR 3,087.99 | 1.93% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.4 | ZAR 1.95T | ZAR 813.97 | 0.86% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.8 | ZAR 424.7B | ZAR 9,973.26 | 1.16% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | ZAR 1.69T | ZAR 16,333.56 | 1.28% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | ZAR 306.3B | ZAR 4,669.82 | 0.32% down | 28% up | ||
| 27 | GSKGSK · Health Care | 16.9 | ZAR 1.68T | ZAR 839.20 | 1.34% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.6 | ZAR 600.6B | ZAR 1,478.18 | 2.50% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.2 | ZAR 2.1T | ZAR 1,028.87 | 2.92% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | ZAR 99.6B | ZAR 146.32 | 1.85% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | ZAR 3T | ZAR 681.13 | 3.12% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | ZAR 345.7B | ZAR 2,580.81 | 4.54% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | ZAR 78.2B | ZAR 714.65 | 1.59% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2745 ZAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (139) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 21:41 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of ZAR 87.39T as of 18 Nov 2026, 21:41 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.